Cannabinoid Stereoselective Synthesis for CB1 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not adequately addressed the isolation, characterization, and biological activity of cannabinoid compounds such as (−)trans (1R,6R) cannabidibutol, (−)trans (1R,6R) Δ9 tetrahydrocannabutol, (−)trans (1R,6R) Δ9 tetrahydro-[Δ9 THCP], and their acid derivatives, which occur in small amounts in nature and lack comprehensive understanding of their therapeutic potential.
Innovation Solution
The development of stereoselective synthesis methods to produce these compounds, including reactions with acidic and basic catalysts, allows for the isolation and characterization of these cannabinoids, confirming their stereochemistry and revealing their affinity to the cannabinoid CB1 receptor, enabling their use in therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If extraction from hemp or hemp cannabinoids is used to obtain cannabinoid compounds, then the compounds can be obtained from natural sources, but the compounds occur in small amounts as impurities requiring complex isolation procedures
Solution Approach 1:
The patent segments the complex natural extraction process into distinct synthetic steps, each producing specific stereoisomers through controlled chemical reactions rather than attempting to extract multiple compounds simultaneously from natural sources
Solution Approach 2:
The patent uses chiral auxiliaries and catalysts as intermediaries to control stereochemistry during synthesis, enabling selective production of desired isomers without complex separation procedures
2Reliability
If natural extraction methods are used to obtain cannabinoid compounds, then the compounds occur in their natural stereochemical configuration, but the compounds occur in small amounts and lack comprehensive stereochemical characterization
Solution Approach 1:
The patent performs preliminary stereochemical characterization through synthetic modeling, creating reference compounds with known configurations before analyzing natural extracts, enabling accurate assignment of absolute stereochemistry even when natural compounds are scarce
Solution Approach 2:
The patent creates synthetic copies of natural cannabinoid compounds with controlled stereochemistry, using these copies as reference standards to characterize the stereochemical configuration of naturally occurring compounds
3Quantity of substance
If conventional synthesis methods are used to produce cannabinoid compounds, then compounds can be produced in larger quantities, but the stereochemical configuration and purity are difficult to control
Solution Approach 1:
The patent applies local quality control at specific reaction centers using chiral catalysts and auxiliaries, ensuring precise stereochemical configuration at key positions while allowing flexibility in other regions of the molecule
Solution Approach 2:
The patent changes physical and chemical parameters such as temperature, solvent, and catalyst structure to control stereochemical outcomes, optimizing both yield and stereoselectivity for each synthesis step
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized cannabinoids demonstrate significant affinity to the CB1 receptor, providing a basis for treating or preventing diseases mediated by this receptor, with potential therapeutic benefits.
Implementation Method 1
The method to produce the cannabinoid compound CBDB of formula (I) comprises reacting (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cycloex-2-enol with 5-butylbenzene-1,3-diol according to scheme (I) in presence of an acidic catalyst, obtaining CBDB. The above reaction (Friedel-Craft allylation)
Implementation Method 2
The intermediate compound of formula (V) is then treated with a basic compound, obtaining Δ9 THCB
Data Source
AI summary
The present disclosure concerns a group of cannabinoid compounds defined by formulas (I) to (IV), wherein R1 is —H or —COOH, for the first time isolated and fully characterized in structure, absolute stereochemistry by the present applicant. Methods of isolation, characterization, stereoselective synthesis, biological activity, pharmaceutical composition and therapeutic applications of the present compounds as modulators of the cannabinoid CB1 receptor are also object of the disclosure.